Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The puropse of this non-interventional register and survey study is to identify the patterns of prescribed pain, anti-depressive and anti-anxiety medication and management of pain, depression and anxiety for people with haemophilia. The study will be conducted in the Nordic countries (Sweden, Norway, Denmark, Finland) and the aim is to cover the entire haemophilia population in the register part of the study.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Part A: Retrospective register study | To describe the usage of prescribed pain, anti-depressive and anti-anxiety medication during a 10-year period based on retrospective data from patient and drug registries. Population: All People with Haemophilia A and B identified through national administrative register or from local register at each treatment centre. The People with Haemophilia group will be compared against an age and gender matched control group from the general population. | ||
| Part B1: Survey to HTC | The survey will be sent out to the relevant physician at each Haemophilia Treatment Centers (HTC) with direct and frequent patient contacts. | ||
| Part B2: Survey to PwH | All People with Haemophilia (PwH) listed at HTCs will be invited to participate in the patient survey. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Use of medication for pain, depression and anxiety (yes/no?) | Based on Registry data | Retrospectively 10 years |
| Annualised consumption of pain medications as assessed by filled prescription | Based on Registry data | Retrospectively 10 years |
| Annualised consumption of anti-anxiety medications as assessed by filled prescription | Based on Registry data | Retrospectively 10 years |
| Annualised consumption of anti-depressive medications as assessed by filled prescription | Based on Registry data | Retrospectively 10 years |
| Duration of pain medications as measured by expected doses of medicines. | Based on Registry data | Retrospectively 10 years |
| Duration of anti-depressive medications as measured by expected doses of medicines. | Based on Registry data | Retrospectively 10 years |
| Duration of anti-anxiety medications as measured by expected doses of medicines. | Based on Registry data | Retrospectively 10 years |
| Pharmacological and non-pharmacological treatments for management of Health-Related Quality of Life (HRQoL) impairment, including treatment of pain |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
All PwH in Sweden, Norway, Denmark and Finland
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Swedish Orphan Biovitrum Research Site | Copenhagen | Denmark | ||||
| Swedish Orphan Biovitrum Research Site |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 40099856 | Derived | Steen Carlsson K, Astermark J, Baghaei F, Brodin E, Funding E, Holmstrom M, Osterholm K, Bergenstrale S, Lethagen S. Comorbidity and Mortality in Men and Women With Haemophilia in Three Nordic Countries-Comparisons to Matched Controls. Haemophilia. 2025 May;31(3):401-411. doi: 10.1111/hae.70023. Epub 2025 Mar 18. | |
| 35460313 | Derived |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006467 | Hemophilia A |
| D002836 | Hemophilia B |
| D001778 | Blood Coagulation Disorders |
| D020147 | Coagulation Protein Disorders |
| D006474 | Hemorrhagic Disorders |
| D030342 | Genetic Diseases, Inborn |
| D010146 | Pain |
| D001008 | Anxiety Disorders |
| ID | Term |
|---|---|
| D025861 | Blood Coagulation Disorders, Inherited |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
Not provided
Not provided
Not provided
Assessed by Health Care Professional (HCP) survey in Part B1 |
| Inclusion in survey study |
| Pharmacological and non-pharmacological treatments for management of HRQoL impairment, including treatment of anxiety | Assessed by HCP survey in Part B1 | Inclusion in survey study |
| Pharmacological and non-pharmacological treatments for management of HRQoL impairment, including treatment of depression | Assessed by HCP survey in Part B1 | Inclusion in survey study |
| The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of pain at each Haemophlia Treatment Centre | Assessed by HCP survey in Part B1 | Inclusion in survey study |
| The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of anxiety at each Haemophlia Treatment Centre | Assessed by HCP survey in Part B1 | Inclusion in survey study |
| The perspective and experience of HCPs with direct and frequent patient Contacts on the strategies for the management of HRQoL impairment, including treatment of depression at each Haemophlia Treatment Centre | Assessed by HCP survey in Part B1 | Inclusion in survey study |
| Self-reported current and previous use of medications for pain | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Self-reported current and previous use of medications for anxiety | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Self-reported current and previous use of medications for depression | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Social and physical activity level | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Euro-QoL 5 Dimensions 5 Levels (EQ-5D-5L) | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Patient satisfaction with current management of pain | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Patient satisfaction with current management anxiety | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Patient satisfaction with current management of depression | Assessed by patient survey in Part B2 | Inclusion in survey study |
| Patient satisfaction of received treatment for pain | Assessed by patient survey in Part B2 | Inclusion in Survey study |
| Patient satisfaction of received treatment for anxiety | Assessed by patient survey in Part B2 | Inclusion in Survey study |
| Patient satisfaction of received treatment for depression | Assessed by patient survey in Part B2 | Inclusion in Survey study |
| Helsinki |
| Finland |
| Swedish Orphan Biovitrum Research Site | Gothenburg | Sweden |
| Swedish Orphan Biovitrum Research Site | Malmö | Sweden |
| Swedish Orphan Biovitrum Research Site | Stockholm | Sweden |
| Steen Carlsson K, Winding B, Astermark J, Baghaei F, Brodin E, Funding E, Holmstrom M, Osterholm K, Bergenstrale S, Andersson E, Lethagen S. Pain, depression and anxiety in people with haemophilia from three Nordic countries: Cross-sectional survey data from the MIND study. Haemophilia. 2022 Jul;28(4):557-567. doi: 10.1111/hae.14571. Epub 2022 Apr 23. |
| D040181 | Genetic Diseases, X-Linked |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001523 | Mental Disorders |